Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
The association of SNRPF with type 2 diabetes mellitus is emerging from multi‐patient studies that interrogate plasma proteomic profiles in large cohorts. In one study, SNRPF was identified as one of four novel proteins significantly associated with type 2 diabetes, with a pQTL signal reaching a p-value of 2.99×10^-14 (PMID:32474106). Although the study did not report specific familial segregation data, the strength of the statistical association suggests that SNRPF may have a biological role in modulating the innate immune response in the context of type 2 diabetes.
From a genetic standpoint, case series and multi‐patient analyses have flagged SNRPF as a candidate gene, yet none of the studies have provided a definitive coding variant—no specific HGVS string (e.g., one starting with “c.” and containing a corresponding protein change) could be extracted from the available data. This lack of a concrete variant, in addition to the absence of reported segregation among affected relatives (0 additional affected relatives noted), limits the current genetic evidence to a modest level.
Functional evidence remains preliminary. Expression studies demonstrate that SNRPF is actively transcribed in tissues that are critical to type 2 diabetes pathogenesis, including liver, pancreas, adipose tissue, and whole blood. However, dedicated functional assays or animal/cellular models specifically addressing the role of SNRPF are lacking. As such, the experimental evidence supporting a direct mechanistic link in the disease process is similarly limited.
Notably, conflicting evidence has emerged from complementary studies. In a Mendelian randomization analysis published in Diabetes Care (PMID:33203707), genetically predicted biomarkers did not support a causal role for plasma vitamin C levels in type 2 diabetes, indirectly challenging the pathogenic relevance of some proteins identified in the pQTL analysis. This discordance underscores the need for further independent replication and functional validation to clarify the impact of SNRPF.
In summary, while significant pQTL evidence implicates SNRPF in type 2 diabetes mellitus, the lack of a clearly defined coding variant, absence of segregation data, and partly conflicting Mendelian randomization findings constrain the overall clinical validity to a Limited level. Further in-depth genetic and functional investigations are needed to firmly establish its role.
Key take‑home sentence: SNRPF represents a promising candidate for type 2 diabetes research, but its clinical utility remains provisional pending additional corroborative evidence.
Gene–Disease AssociationLimitedThe association is supported by significant pQTL findings (p = 2.99×10^-14 [PMID:32474106]) in a multi‐patient study, yet the absence of clear segregation data and conflicting Mendelian randomization results ([PMID:33203707]) constrain its validity. Genetic EvidenceLimitedAlthough SNRPF was identified among significant plasma protein quantitative trait loci, no specific coding variant or familial segregation information is provided to robustly support disease causality. Functional EvidenceLimitedExpression across type 2 diabetes–relevant tissues suggests a potential role for SNRPF; however, the lack of targeted functional assays and mechanistic studies limits the strength of this evidence. |